V. Avramis

发表

Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

H. Sather, P. Steinherz, P. Gaynon, 2004, Journal of pediatric hematology/oncology.

Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.

V. Avramis, J. Holcenberg, B. Antonsson, 1987, Cancer research.

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines

Edward A. Sausville, Walter E. Laug, E. Sausville, 2003, Cancer Chemotherapy and Pharmacology.

Pharmacodynamic and DNA methylation studies of high-dose 1-β-d-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia

V. Avramis, J. Holcenberg, J. Nyce, 2004, Cancer Chemotherapy and Pharmacology.

Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia

D. Hawkins, E. Panosyan, V. Avramis, 2004, Clinical Cancer Research.

Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations

E. Panosyan, V. Avramis, 2005, Clinical pharmacokinetics.

Asparaginases: A Successful Class of Drugs Against Leukemias and Lymphomas

V. Avramis, 2011, Journal of pediatric hematology/oncology.

Asparaginases: biochemical pharmacology and modes of drug resistance.

V. Avramis, 2012, Anticancer research.

Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation

J. Villablanca, C. Reynolds, Anis A. Khan, 1996, Cancer Chemotherapy and Pharmacology.

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.

K. Matthay, R. Seeger, J. Villablanca, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.

S. Mittelman, V. Avramis, M. Maggi, 2015, Leukemia research.

Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

S. Mittelman, V. Avramis, S. Louie, 2010, Pharmacological research.

Childhood Acute Leukemia1

S. Siegel, M. Krailo, J. Finklestein, 2006 .

Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.

P. Danenberg, L. Cohen, V. Avramis, 1998, Anticancer research.

Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group report

D. Radvinsky, Tamekia Jones, P. Gaynon, 2015, Cancer.

Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice

V. Avramis, W. Powell, 2004, Cancer Chemotherapy and Pharmacology.

Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.

I. Avramis, V. Avramis, R. Kwock, 2001, Anticancer research.

Protein phosphatase 1α-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein

N. Berndt, C. Liu, V. Avramis, 2001, Oncogene.

Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.

W. Evans, J. Irvin, V. Avramis, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinosyl-2-fluoroadenine

W. Plunkett, V. Avramis, 1983 .

2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.

W. Plunkett, V. Avramis, 1983, Biochemical and biophysical research communications.

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

M. Tallman, I. Aldoss, M. Lunning, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

A. Periclou, A. Levine, D. Douer, 2007, Blood.

Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines

V. Avramis, L. V. Ramilo-Torno, 2004, Cancer Chemotherapy and Pharmacology.

Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).

V. Avramis, M. C. Long, William Hunter, 2009, Anticancer research.

Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

S. Martín-Aragón, V. Avramis, B. Asselin, 2007, Anticancer research.

Assessment of Anti-Asparaginase (ASNase) Antibodies (Ab) and ASNase Activity after Suspected Clinical Allergy.

J. Quinn, P. Gaynon, S. Siegel, 2006 .

Synthesis and Testing of New Antileukemic Schiff Bases of N-Hydroxy-N′ - Aminoguanidine Against CCRF-CEM/0 Human Leukemia Cells in Vitro and Synergism Studies with Cytarabine (Ara-C)

E. Lien, V. Avramis, P. Koneru, 1993, Pharmaceutical Research.

Antileukemic activity studies and cellular pharmacology of the analogues of 2-hydroxy-1H-isoindole-1,3-dione (HISD) alone and in combination with cytosine arabinoside (ara-C) against human leukemia cells CEM/0.

E. Lien, V. Avramis, P. Nandy, 1994, Acta oncologica.

SYNERGISTIC COMBINATIONS OF NUCLEOSIDE ANALOG DRUGS WITH OTHER DRUGS INDUCE GREATER APOPTOSIS IN HUMAN LEUKEMIC T-CELLS

A. Periclou, V. Avramis, P. Nandy, 1997 .

Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice.

V. Avramis, 1989, Cancer investigation.

Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia.

W. Plunkett, V. Avramis, 1983, Cancer drug delivery.

Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.

W. Plunkett, V. Avramis, 1982, Cancer research.

Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-)

V. Avramis, W. Powell, Robert A. Mecum, 2004, Cancer Chemotherapy and Pharmacology.

Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).

P. Gaynon, H. Fingert, S. Siegel, 2004, Anticancer research.

Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).

P. Gaynon, E. Panosyan, N. Seibel, 2004, In vivo.

Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection.

V. Avramis, E. Gomperts, R. Kwock, 1993, Journal of acquired immune deficiency syndromes.

Biochemical pharmacology of zidovudine in human T‐lymphoblastoid cells (CEM)

V. Avramis, R. Jackson, E. Gomperts, 1989, AIDS.

Phase I Study of Gemcitabine (Difluorodeoxycytidine) in Children with Relapsed or Refractory Leukemia (CCG-0955): A Report from the Children's Cancer Group

G. Reaman, P. Steinherz, J. Reid, 2002, Leukemia & lymphoma.

Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.

G. Reaman, M. Krailo, V. Avramis, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.

K. Schmiegelow, H. Müller, V. Avramis, 2002, Medical and pediatric oncology.

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

K. Schmiegelow, H. Müller, J. Ingerslev, 2001, British journal of haematology.

Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy.

P. Gaynon, L. Ettinger, V. Avramis, 1997, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

V. Avramis, P. Tiwari, 2006, International journal of nanomedicine.

Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.

E. Lien, V. Avramis, P. Nandy, 1999, Anticancer research.

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

J. Neglia, H. Sather, B. Druker, 2002, Blood.

New approaches to overcome drug resistance

V. Avramis, J. Holcenberg, R. Biener, 1987 .

NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias

A. Periclou, V. Avramis, 1996, Cancer Chemotherapy and Pharmacology.

Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.

K. Weinberg, T. Coates, V. Avramis, 1989, Cancer research.

Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.

V. Avramis, J. Ortega, M. Ozkaynak, 1998, Medical and pediatric oncology.

Cellular metabolism of 1-β-d-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(−) cells

V. Avramis, W. Powell, Robert A. Mecum, 2004, Cancer Chemotherapy and Pharmacology.

Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse

S. Meshinchi, D. Hawkins, M. Loken, 2004, Pediatric blood & cancer.

Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.

S. Mittelman, A. Butturini, V. Avramis, 2013, Cancer research.

Adipocytes impair leukemia treatment in mice.

N. Heisterkamp, A. S. Moses, S. Mittelman, 2009, Cancer research.

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

E. Sausville, W. Laug, G. McNamara, 2002, Cancer Chemotherapy and Pharmacology.

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.

G. Reaman, M. Krailo, N. Seibel, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

Lingyun Ji, R. Sposto, P. Gaynon, 2015, Pediatric blood & cancer.

Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.

C. Fu, S. Martín-Aragón, V. Avramis, 2000, Anticancer research.

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG‐1941)

David Steele, D. Stram, M. Trigg, 2006, Pediatric blood & cancer.

Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric ALL Patients

V. Avramis, S. Spence, 2007, Journal of pediatric hematology/oncology.

Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.

K. Weinberg, S. Martín-Aragón, V. Avramis, 2001, Anticancer research.

Biochemical pharmacology and DNA methylation studies of arabinosyl 5‐azacytidine and 5,6‐dihydro‐5‐azacytidine in two human leukemia cell lines PER‐145 and PER‐163

U. Kees, V. Avramis, 1995, Anti-cancer drugs.

Is glutamine depletion needed in ALL disease?

V. Avramis, 2014, Blood.

Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid.

J. Villablanca, C. Reynolds, V. Avramis, 1993, The American journal of pediatric hematology/oncology.

Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962

F. Dorey, E. Panosyan, I. Avramis, 2006, Clinical Cancer Research.

Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.

V. Avramis, W. Powell, 1987, Cancer investigation.

Preclinical pharmacology of the antitumor agentO-6-methylguanine in CDF1 mice

V. Avramis, M. M. Solorzano, Zhanwei Chen, 2004, Cancer Chemotherapy and Pharmacology.

Idiopathic thrombocytopenic purpura , Helicobacter pylori infection , and HLA class II alleles

V. Avramis, J. Holcenberg, 2022 .

Structure-function relationships and clinical applications of L-asparaginases.

A. Papageorgiou, N. Labrou, V. Avramis, 2010, Current medicinal chemistry.

The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.

A. Periclou, V. Avramis, P. Nandy, 1998, Anticancer research.

Asparagine Synthetase Polymorphisms and Toxicity and Efficacy of Asparaginases

V. Avramis, 2014, Clinical Cancer Research.

Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.

C. Inderlied, I. Avramis, L. Cohen, 2001, In vivo.

High-Grade Pegylated Asparaginase-Related Hepatotoxicity Occurrence In a Pediatric-Inspired Adult Acute Lymphoblastic Leukemia Regimen Does Not Necessarily Predict Recurrent Hepatotoxicity In Subsequent Cycles

M. Tallman, I. Aldoss, M. Lunning, 2013 .

Arandomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia : a Children ’ s Cancer Group study

J. Neglia, H. Sather, B. Lange, 2002 .

Pharmacodynamic (PD) Analyses of Asparagine (Asn) Deamination and Asn Input (Imax) in Serum of Pediatric Patients with Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Receiving Native or Pegylated E. Coli Asparaginases (ASNase) (CCG-1962).

P. Gaynon, E. Panosyan, C. Fu, 2004 .

Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study

K. Schmiegelow, V. Avramis, H. Schrøder, 2002, Cancer Chemotherapy and Pharmacology.

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein

K. Weinberg, P. Danenberg, C. Fu, 2001, Cancer Chemotherapy and Pharmacology.

Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene.

V. Avramis, X. Liu, R. Kwock, 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

A. Periclou, A. Levine, D. Douer, 2007, Blood.

H. Sather, B. Lange, P. Gaynon, 2002, Blood.

Asparaginases: A Successful Class of Drugs Against Leukemias and Lymphomas

V. Avramis, 2011, Journal of pediatric hematology/oncology.